FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367668180> ?p ?o ?g. }

• W4367668180 endingPage "2693" @default.
• W4367668180 startingPage "2685" @default.
• W4367668180 abstract "Abstract Background In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell‐cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities. Here, clinical safety and early efficacy data are presented on the combination of pembrolizumab and an oral selective nuclear export inhibitor, selinexor, for the treatment of metastatic non–small cell lung cancer (mNSCLC). Methods The primary objective of this prospective investigator‐initiated study was to determine the safety and tolerability of selinexor in combination with pembrolizumab in patients with mNSCLC. Secondary objectives included determination of objective tumor response rate, disease control rate, and progression‐free survival duration. Results A total of 17 patients were included in the final analysis. Fifteen (88%) received more than two lines of prior systemic therapy and 10 (59%) had prior exposure to anti–PD‐1/programmed death‐ligand 1 (PD‐L1) therapy. The median age was 67.5 years. Ten patients had grade ≥3 adverse events related to selinexor treatment. Responses to treatment occurred in patients who did and did not undergo previous anti–PD‐1/PD‐L1 therapy and in patients with activating driver mutations. The median overall survival and progression‐free survival were 11.4 months (95% CI, 3.4–19.8 months) and 3.0 months (95% CI, 1.7–5.7 months), respectively. The overall response rate was 18% and the 6‐month disease control rate was 24%. Conclusions Selinexor in combination with pembrolizumab demonstrated promising antitumor activity in patients with mNSCLC, including those who had previously received anti–PD‐1/PD‐L1 therapy. The therapy‐related toxic effects were consistent with the prior safety data for both drugs, and no overlapping toxic effects were observed. Trial registration ClinicalTrials.gov identifier: NCT02419495. Plain language summary New strategies to prevent or reverse resistance to immune checkpoint inhibitors are under investigation. Selective inhibitors of nuclear export proteins, such as selinexor, can induce restoration of tumor‐suppressing pathways and induce potent immunomodulatory activities. This article contains the clinical safety and early efficacy data on the combination of pembrolizumab and selinexor in treatment of metastatic non–small cell lung cancer." @default.
• W4367668180 created "2023-05-03" @default.
• W4367668180 creator A5005436649 @default.
• W4367668180 creator A5008786567 @default.
• W4367668180 creator A5009466654 @default.
• W4367668180 creator A5036987409 @default.
• W4367668180 creator A5039103793 @default.
• W4367668180 creator A5039395364 @default.
• W4367668180 creator A5041930095 @default.
• W4367668180 creator A5048380048 @default.
• W4367668180 creator A5050140548 @default.
• W4367668180 creator A5053220315 @default.
• W4367668180 creator A5069676375 @default.
• W4367668180 creator A5077579849 @default.
• W4367668180 creator A5079762645 @default.
• W4367668180 date "2023-05-02" @default.
• W4367668180 modified "2023-10-17" @default.
• W4367668180 title "Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer" @default.
• W4367668180 cites W2011275571 @default.
• W4367668180 cites W2019607817 @default.
• W4367668180 cites W2028885314 @default.
• W4367668180 cites W2082627972 @default.
• W4367668180 cites W2082739624 @default.
• W4367668180 cites W2290633618 @default.
• W4367668180 cites W2526506448 @default.
• W4367668180 cites W2735287048 @default.
• W4367668180 cites W3088980765 @default.
• W4367668180 cites W3124080354 @default.
• W4367668180 cites W3136214606 @default.
• W4367668180 cites W3186741379 @default.
• W4367668180 cites W4281721227 @default.
• W4367668180 cites W4309503973 @default.
• W4367668180 doi "https://doi.org/10.1002/cncr.34820" @default.
• W4367668180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37129197" @default.
• W4367668180 hasPublicationYear "2023" @default.
• W4367668180 type Work @default.
• W4367668180 citedByCount "1" @default.
• W4367668180 countsByYear W43676681802023 @default.
• W4367668180 crossrefType "journal-article" @default.
• W4367668180 hasAuthorship W4367668180A5005436649 @default.
• W4367668180 hasAuthorship W4367668180A5008786567 @default.
• W4367668180 hasAuthorship W4367668180A5009466654 @default.
• W4367668180 hasAuthorship W4367668180A5036987409 @default.
• W4367668180 hasAuthorship W4367668180A5039103793 @default.
• W4367668180 hasAuthorship W4367668180A5039395364 @default.
• W4367668180 hasAuthorship W4367668180A5041930095 @default.
• W4367668180 hasAuthorship W4367668180A5048380048 @default.
• W4367668180 hasAuthorship W4367668180A5050140548 @default.
• W4367668180 hasAuthorship W4367668180A5053220315 @default.
• W4367668180 hasAuthorship W4367668180A5069676375 @default.
• W4367668180 hasAuthorship W4367668180A5077579849 @default.
• W4367668180 hasAuthorship W4367668180A5079762645 @default.
• W4367668180 hasConcept C121608353 @default.
• W4367668180 hasConcept C126322002 @default.
• W4367668180 hasConcept C143998085 @default.
• W4367668180 hasConcept C197934379 @default.
• W4367668180 hasConcept C2776256026 @default.
• W4367668180 hasConcept C2777701055 @default.
• W4367668180 hasConcept C2778375690 @default.
• W4367668180 hasConcept C2778822529 @default.
• W4367668180 hasConcept C2779134260 @default.
• W4367668180 hasConcept C2779984678 @default.
• W4367668180 hasConcept C2780057760 @default.
• W4367668180 hasConcept C71924100 @default.
• W4367668180 hasConceptScore W4367668180C121608353 @default.
• W4367668180 hasConceptScore W4367668180C126322002 @default.
• W4367668180 hasConceptScore W4367668180C143998085 @default.
• W4367668180 hasConceptScore W4367668180C197934379 @default.
• W4367668180 hasConceptScore W4367668180C2776256026 @default.
• W4367668180 hasConceptScore W4367668180C2777701055 @default.
• W4367668180 hasConceptScore W4367668180C2778375690 @default.
• W4367668180 hasConceptScore W4367668180C2778822529 @default.
• W4367668180 hasConceptScore W4367668180C2779134260 @default.
• W4367668180 hasConceptScore W4367668180C2779984678 @default.
• W4367668180 hasConceptScore W4367668180C2780057760 @default.
• W4367668180 hasConceptScore W4367668180C71924100 @default.
• W4367668180 hasFunder F4320309542 @default.
• W4367668180 hasFunder F4320337351 @default.
• W4367668180 hasIssue "17" @default.
• W4367668180 hasLocation W43676681801 @default.
• W4367668180 hasLocation W43676681802 @default.
• W4367668180 hasOpenAccess W4367668180 @default.
• W4367668180 hasPrimaryLocation W43676681801 @default.
• W4367668180 hasRelatedWork W1584669207 @default.
• W4367668180 hasRelatedWork W2024340610 @default.
• W4367668180 hasRelatedWork W2024938637 @default.
• W4367668180 hasRelatedWork W2121180524 @default.
• W4367668180 hasRelatedWork W2899528185 @default.
• W4367668180 hasRelatedWork W2899585536 @default.
• W4367668180 hasRelatedWork W3030034569 @default.
• W4367668180 hasRelatedWork W3031735911 @default.
• W4367668180 hasRelatedWork W3172671185 @default.
• W4367668180 hasRelatedWork W3194663175 @default.
• W4367668180 hasVolume "129" @default.
• W4367668180 isParatext "false" @default.
• W4367668180 isRetracted "false" @default.
• W4367668180 workType "article" @default.